Simplify everything from site selection to study close-out
Velocity unifies operational processes to provide world-class sites, reliable enrollment, and predictably high performance for your trials.
News
Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network
As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a … Read more
VISION Reaches $2.5 Million in Patient Stipends Paid Globally
Another major milestone for Velocity — more than $2.5 million in patient study stipends have been paid globally through our VISION Engage app! With VISION Engage, patients can seamlessly manage … Read more
Dr. Watz Publishes 250th Paper, Leads Velocity’s Ahrensburg, Germany Site as the Top Enroller for a Global COPD Trial
Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just … Read more
Ipsen’s Iqirvo Approved for Use in EU Based on Results Authored by Kris Kowdley, MD
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, played an integral role in the clinical research that first gained FDA approval in June 2024, and has now led to the European … Read more